Momenta Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Momenta Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Momenta Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Momenta Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Momenta Pharmaceuticals, Inc.

The report provides overview of Momenta Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Momenta Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Momenta Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Momenta Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Momenta Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Momenta Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Momenta Pharmaceuticals, Inc. Snapshot 6

Momenta Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Momenta Pharmaceuticals, Inc. - Research and Development Overview 7

Key Therapeutic Areas 7

Momenta Pharmaceuticals, Inc. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Momenta Pharmaceuticals, Inc. - Pipeline Products Glance 12

Momenta Pharmaceuticals, Inc. - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

Momenta Pharmaceuticals, Inc. - Drug Profiles 17

adalimumab biosimilar 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

necuparanib 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

M-281 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

abatacept biosimilar 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Antibody for Autoimmune Disorders and Inflammation 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

M-230 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

M-615 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

M-706 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

M-710 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

M-730 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

M-740 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibodies for Autoimmune Diseases 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Momenta Pharmaceuticals, Inc. - Pipeline Analysis 30

Momenta Pharmaceuticals, Inc. - Pipeline Products by Target 30

Momenta Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 31

Momenta Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 32

Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 33

Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates 34

Momenta Pharmaceuticals, Inc. - Dormant Projects 39

Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products 40

Discontinued Pipeline Product Profiles 40

bevacizumab biosimilar 40

Momenta Pharmaceuticals, Inc. - Company Statement 41

Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Momenta Pharmaceuticals, Inc., Key Information 6

Momenta Pharmaceuticals, Inc., Key Facts 6

Momenta Pharmaceuticals, Inc. – Pipeline by Indication, 2016 8

Momenta Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Momenta Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Momenta Pharmaceuticals, Inc. – Phase III, 2016 12

Momenta Pharmaceuticals, Inc. – Phase II, 2016 13

Momenta Pharmaceuticals, Inc. – Phase I, 2016 14

Momenta Pharmaceuticals, Inc. – Preclinical, 2016 15

Momenta Pharmaceuticals, Inc. – Discovery, 2016 16

Momenta Pharmaceuticals, Inc. – Pipeline by Target, 2016 30

Momenta Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 31

Momenta Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 32

Momenta Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 33

Momenta Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 34

Momenta Pharmaceuticals, Inc. – Dormant Developmental Projects,2016 39

Momenta Pharmaceuticals, Inc. – Discontinued Pipeline Products, 2016 40

Momenta Pharmaceuticals, Inc., Subsidiaries 43

List of Figures

List of Figures

Momenta Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 8

Momenta Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 10

Momenta Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 11

Momenta Pharmaceuticals, Inc. – Pipeline by Top 10 Target, 2016 30

Momenta Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 31

Momenta Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 32

Momenta Pharmaceuticals, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 33

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports